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Abstract
Adsorption nature of attapulgite may inhibit the absorption of ciprofloxacin after oral administration. 
As a result, this drug-drug interaction may reduce ciprofloxacin bioavailability. This study was aimed to 
determine the effect of attapulgite on the bioavailability of a single orally-administered ciprofloxacin. 
Six New Zealand white rabbits received each of the following treatments in a randomized, three-way 
crossover sequence, separated by a 7-day washout period: (i) ciprofloxacin (23 mg/kgBW) alone; (ii) 
ciprofloxacin (23 mg/kgBW) given simultaneously with attapulgite (28 mg/kgBW); (iii) ciprofloxacin 
(23 mg/kgBW) given 2 hours after attapulgite (28 mg/kgBW). Blood samples (1 mL) were collected 
from the marginal ear vein up to 240 minutes postdose. The plasma concentrations of ciprofloxacin 
were determined by a validated high-performance liquid chromatography method. The maximum 
concentration and oral bioavailability (AUC0-240 min) of ciprofloxacin were significantly decreased by 
49% and 32% when administered concomitantly with attapulgite (p<0.001). Attapulgite appeared to 
have no significant effect on the bioavailability of ciprofloxacin when administered 2 hours before 
ciprofloxacin. In conclusion, the oral bioavailability of ciprofloxacin is markedly reduced when 
administered concomitantly with attapulgite. This drug-drug interaction may decrease clinical efficacy 
and promote microbial resistance to ciprofloxacin. However, the interaction could be minimized by 
separating the adminsitration of these drugs at least 2 hours.
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Pengaruh Atapulgit pada Ketersediaan Hayati Siprofloksasin Oral
Abstrak
Kemampuan absorpsi atapulgit dapat menghambat absorpsi siprofloksasin pada pemberian per oral. 
Sebagai hasilnya, interaksi obat-obat ini dapat menurunkan ketersediaan hayati siprofloksasin. Penelitian 
ini bertujuan untuk mendeterminasi efek atapulgit pada ketersediaan hayati obat siprofloksasin yang 
diberikan secara oral. Sebanyak 7 kelinci putih Selandia Baru menerima perlakuan secara random dengan 
desain three-way crossover sequence, yang dipisahkan dengan periode washout 7 hari. (i) siprofloksasin 
(23 mg/kgBB); (ii) siprofloksasin (23 mg/kgBB) diberikan secara simultan dengan atapulgit (28 mg/
kgBB); (iii) siprofloksasin (23 mg/kgBB) diberikan 2 jam setelah pemberian atapulgit (28 mg/kgBB. 
Sampel darah (1 mL) dikumpulkan pada marginal ear vein setelah 240 menit pemberian obat. Konsentrasi 
siprofloksasin plasma dihitung dengan metode kromatografi cair kinerja tinggi tervalidasi. Konsentrasi 
maksimum dan ketersediaan hayati oral (AUC0-240 min) siprofloksasin secara signifikan berkurang 49% dan 
32% ketika dikombinasikan bersamaan dengan atapulgit (p< 0,001). Atapulgit tidak memiliki pengaruh 
signifikan pada ketersediaan hayati ketika diberikan 2 jam sebelum siprofloksasin. Ketersediaan hayati 
siprofloksasin berkurang secara signifikan ketika diberikan bersamaan dengan pemberian atapulgit. 
Interaksi obat dengan obat ini dapat mengurangi efikasi obat dan meningkatkan resistensi mikrob terhadap 
siprofloksasin. Namun, interaksi dapat dikurangi dengan pemberian obat pada jarak waktu minimal  2 jam.
Kata kunci: Atapulgit, interaksi obat dengan obat, ketersediaan hayati, siprofloksasin
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Introduction
Ciprofloxacin is a second-generation of 
fluoroquinolone which exhibits in vitro 
minimum inhibitory concentrations (MICs) 
of 1 μg/mL against most (≥90%) strains of 
aerobic Gram-positive and Gram-negative 
microorganisms.1 Ciprofloxacin given as 
an oral tablet is well absorbed from the 
gastrointestinal tract after oral administration. 
The absolute bioavailability is 70 to 80% with 
no substantial loss by first pass metabolism.2 
Maximum serum concentrations are attained 
1 to 2 h after oral dosing and its serum 
concentration after oral administration is 
similar to the intravenous route.2 
Food and drugs which have divalent (Ca+2, 
Fe+2, Mg+2, Zn+2) or trivalent (Al+3, Fe+3) 
cations may interact with ciprofloxacin by 
forming chelate complexes thus reducing the 
rate and amount of ciprofloxacin absorption 
in the upper gastrointestinal tract.1,3,4 A 
research by Garrelts et al.5 showed a decrease 
in the bioavailability of ciprofloxacin in 
healthy humans after a concurrent use of 
500 mg ciprofloxacin with 1 gram sucralfate 
which has 16 aluminum ions per molecule. A 
sucralfate-ciprofloxacin interaction causes a 
decrease in the area under the concentration-
time curve (0 to 12 h) of 8.8 to 1.1 μg.h/mL 
(p<0.005) and the maximum concentration of 
ciprofloxacin in the serum of 2.0 to 0.2 mg/
mL (p<0.005).5 Another study revealed that 
the bioavailability of 750 mg ciprofloxacin 
reduced respectively by 7%, 20% and 95% 
when given sucralfate consecutive 6 h before, 
2 h before and at the same time.6 Further 
results of reduced bioavailability of this drug 
may impact to the effectiveness of therapy, 
even though the study does not address any 
impact on antibiotic therapy outcomes.
A drug-drug interaction with a chelate 
formation mechanism may also occur when 
ciprofloxacin is concurrently administered 
with attapulgite. Attapulgite, a hydrated 
magnesium aluminum silicate, has aluminum 
cations which can bind to the carboxylic 
acid and ketone groups at positions 3 
and 4 on the ciprofloxacin nucleus thus 
forming nonabsorbable chelate complexes. 
Furthermore, adsorption nature of 
attapulgite may also inhibit the absorption of 
ciprofloxacin after oral administration. As a 
result, this drug-drug interaction may reduce 
ciprofloxacin bioavailability. However, there 
are no recent studies reported on the issue. 
Therefore, the purpose of this study was to 
determine the effect of attapulgite on the 
bioavailability of a single orally-administered 
ciprofloxacin.
Methods
Six New Zealand white rabbits received each 
of the following treatments in a randomized, 
three-way crossover sequence, separated by 
a 7-day washout period: (i) ciprofloxacin (23 
mg/kgBW) alone; (ii) ciprofloxacin (23 mg/
kgBW) given simultaneously with attapulgite 
(28 mg/kgBW); (iii) ciprofloxacin (23 mg/
kgBW) given 2 h after attapulgite (28 mg/
kgBW). The rabbits were fasted overnight 
prior to treatments and given free access to 
water. Blood samples (1 mL) were collected 
from the marginal vein of the ear at 0, 20, 40, 
60, 90, 120, 180, and 240 minutes postdose. 
Samples were collected into sterile vacuum 
tubes and centrifuged at 4,000 rpm for 15 
minutes. Plasma was obtained and stored in 
a sterile microtube at -20°C until analyzed. 
The plasma concentrations of ciprofloxacin 
were determined by a validated high-
performance liquid chromatography assay 
and a modification of the method reported by 
USP.7 Briefly, 200.0 µL of spiked standards 
(ciprofloxacin 3.0 μg/mL) was added to 200.0 
µL of plasma, and the mixture was vortexed 
for 60 s. Next, 200.0 µL of acetonitrile and 
100.0 µL of H3PO4 0.02 M (pH 3.0, adjusted 
with triethanolamine) were added to the 
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mixture and then centrifuged at 4,000 rpm 
for 20 minutes. The supernatant was filtered 
by a 0.2 µL filter membrane and then 10.0 
µL of solution was injected into the HPLC 
system.
The chromatographic system was 
composed of a HPLC-DAD Agilent 1100 
series, diode array detector, and Licrospher 
ODS @ 100 RP-18 column. The detector 
wavelength was set to 280 nm. Mixtures of 
acetonitrile:H3PO4 0,02 M (pH 3, adjusted 
with triethanolamine) (13:87, v/v) were 
used as the mobile phase at a flow rate of 
1.5 mL/min. The retention time is 9.2 min. 
The calibration curve of ciprofloxacin was 
linier within range 0.25 to 10.0 µg/mL 
(r=0.9997). Detection limit was 0.02 µg/mL 
and quantification limit was 0.06 μg/mL. 
The within-day (n=5) and day-to-day (n=5) 
coefficient of variation was 1.98±0.65%. 
Recovery (%) was assessed from replicate 
analysis (n=6) and shown 99.54±7.13%.
The maximum concentration and the time 
of maximum concentration of ciprofloxacin 
in plasma were obtained directly from 
the plasma concentration-time curve for 
each subject. The area under the plasma 
concentration-time curve from 0 to 240 
min (AUC0-240) was calculated by using the 
linear trapezoidal rule method. Differences 
in the mean AUC0-240min and the maximum 
ciprofloxacin concentrations among 
the treatment groups were analyzed for 
significance by a two-way ANOVA with an 
alpha value of 0.05.
Results
The plasma concentrations of ciprofloxacin 
after the oral administration of ciprofloxacin 
alone, co-administered with attapulgite, and 
2 hours after attapulgite to rabbits are shown 
in Table 1 and Figure 1.  
The plasma concentrations of ciprofloxacin 
were altered when ciprofloxacin was given 
Figure 1 Mean Plasma Ciprofloxacin 
Concentration-versus-time 
Profiles for Ciprofloxacin 
23 mg/kgBW Alone ( ), 
Ciprofloxacin 23 mg/kgBW 
with Attapulgite 28 mg/kgBW 
( ), and Ciprofloxacin 23 mg/
kgBW 2 h after Attapulgite 
28 mg/kgBW ( ). Values are 
Means±Standard Errors
concomitantly with attapulgite. The maximum 
concentration and bioavailability (AUC0-240 
min) of ciprofloxacin decreased by 49% and 
32% when attapulgite was administered 
concomitantly (p<0.001). However, 
concurrent administration of attapulgite 
did not affect the time to reach maximum 
plasma concentration of ciprofloxacin after 
oral administration. Furthermore, attapulgite 
appeared to have no significant effect on 
the bioavailability of ciprofloxacin when 
administered 2 h before ciprofloxacin.
The plasma concentrations of ciprofloxacin 
were altered when ciprofloxacin was 
given concomitantly with attapulgite. The 
maximum concentration and bioavailability 
(AUC0-240 min) of ciprofloxacin decreased 
by 49% and 32% when attapulgite was 
administered concomitantly (p<0.001). 
However, concurrent administration 
of attapulgite did not affect the time to 
reach maximum plasma concentration of 
ciprofloxacin after oral administration. 
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Table 1    Pharmacokinetic Parameters of Ciprofloxacin in Rabbits After a Single Oral Dose 
              of 23 mg/KgBW Given Alone, with 28 mg/KgBW Attapulgite, and 2 Hours After 
               Attapulgite
Treatment Group
C
max
t
max
(min
AUC0-360
µg/mL
% decrease 
(compared 
to control)
µg.min/mL
%decrease 
(compared 
to control)
Ciprofloxacin alone (control) 3.69 ± 0.37 90 12.68 ± 1.66
Ciprofloxacin with attapulgite 1.86 ± 0.57 49.6b 90 8.57 ± 1.92 32.4b
Ciprofloxacin 2 h after attapulgite 3.38 ± 0.77 8.40c 90 9.67 ± 0.58 23.7c
Note: a Data are mean values (± standard deviations as appropriate) for six subjects
    b Significantly different (p < 0.001) from control
    c No significantly different (p > 0.001) from control
Furthermore, attapulgite appeared to have 
no significant effect on the bioavailability of 
ciprofloxacin when administered 2 h before 
ciprofloxacin.
Discussion
The absorption process plays an important 
role in achieving maximum concentrations 
and bioavailability of drugs in the systemic 
Figure 2 Chelate Formation between 
a Chelating Agent which Has 
Cations and Fluoroquinolones
 
R1 = -CH(CH3)-CH2 ; R2 = -O- ; R3 = CH3 ; R4 = H 
Fluoroquinolone 
M = chelating agent 
Fluoroquinolone 
circulation.8 If there are either drug-drug or 
drug-food interactions during an absorption 
phase, it will reduce the amount of drug 
that enters the body hence reducing the 
bioavailability of drug. The present study 
demonstrated that the effects of concomitant 
ingestion of attapulgite were pronounced 
decreases in maximum concentrations 
(C
max
) and bioavailability (AUC0-240min) of 
ciprofloxacin. 
The most plausible explanation for 
attapulgite-ciprofloxacin interaction is 
the formation of chelate complexes.9 
Attapulgite which acts as an adsorbent in the 
gastrointestinal tract has a capacity to bind 
drug molecules to its surface area. Next, its 
aluminum cations (Al+3) may interact with the 
4-keto and 3-carboxyl groups of ciprofloxacin 
to form chelate complexes thus reducing the 
rate and amount of ciprofloxacin absorption 
in the gastrointestinal tract.1,4,5 Figure 2 shows 
the possible mechanism of chelate formation 
between attapulgite and ciprofloxacin. When 
ciprofloxacin was given concomitantly with 
attapulgite, there were many aluminum 
cations available to interact with the 4-keto 
and 3-carboxyl groups of ciprofloxacin. Only 
a small amount of ciprofloxacin was left to be 
absorbed into the systemic circulation hence From: El-Kommos et al.9
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reducing the bioavailability and maximum 
plasma concentration of ciprofloxacin.
Some investigators have evaluated the 
effect of staggered dosing of fluoroquinolones 
and sucralfate on the extent of drug-
drug interaction.5,6 Sucralfate which has 
aluminum cations appeared to reduce the 
bioavailability of ciprofloxacin by 88% (with 
1 g of sucralfate administered four times on 
the day before the study and the fifth dose 
given with ciprofloxacin). However, when 
a 1 g dose of sucralfate was given 6 and 2 
h before ciprofloxacin, only a 30% decrease 
in the bioavailability of ciprofloxacin was 
observed.5 Clearly, not only the time interval 
between administrations of these interacting 
drugs, but also the sequence in which they 
are given, is important when trying to prevent 
this potential interaction. 
Of additional importance, when attapulgite 
was administered 2 h before ciprofloxacin, it 
failed to significantly affect the bioavailability 
of ciprofloxacin. It means that the amount of 
attapulgite contained in the rabbit stomach 
may begin to diminish as the process of 
gastric emptying (3 to 6 h).10 As a result, 
this potential drug-drug interaction could be 
minimized by separating the intake of these 
drugs at least 2 h. Moreover, the maximum 
concentration of ciprofloxacin in plasma was 
achieved in less than 2 h, so it is reasonable 
to assume that the absorption process was 
completed before ciprofloxacin came into 
contact with released aluminum ions when 
ciprofloxacin given 2 h before attapulgite.
This present study does not investigate 
the impact of drug-drug interaction on 
decreasing the effectiveness of therapy. 
Nonetheless, further studies on assessing the 
clinical outcomes from the concomitant use 
of attapulgite and ciprofloxacin are needed 
to address this issue. Ciprofloxacin exhibits 
in vitro minimum inhibitory concentrations 
(MICs) of 1 μg/mL against most (≥ 90%) 
strains of aerobic gram-positive and gram-
negative microorganisms.1 Therefore, if 
plasma concentrations of ciprofloxacin fall 
below its MICs then the effectiveness of 
ciprofloxacin in treating clinical infections 
will be questioned. 
Conclusions
The oral bioavailability of ciprofloxacin 
was markedly reduced when administered 
concomitantly with attapulgite. This drug-
drug interaction may decrease clinical 
efficacy and promote microbial resistance to 
ciprofloxacin. However, the interaction could 
be minimized by separating the adminsitration 
of these drugs at least 2 h.
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